New drug combo targets root cause of cystic fibrosis
NCT ID NCT02070744
Summary
This study tested the safety and effectiveness of a two-drug combination (VX-661 and ivacaftor) for people with cystic fibrosis who have two copies of the most common genetic mutation (F508del). Forty participants were randomly assigned to receive either the drug combination or a placebo for 12 weeks, followed by an optional period where everyone could receive the active drugs. Researchers measured lung function, sweat chloride levels, weight, and quality of life to see if the treatment helped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Birmingham, Alabama, United States
-
Study site
Palo Alto, California, United States
-
Study site
Stanford, California, United States
-
Study site
Altamonte Springs, Florida, United States
-
Study site
Miami, Florida, United States
-
Study site
Orlando, Florida, United States
-
Study site
Tampa, Florida, United States
-
Study site
Boise, Idaho, United States
-
Study site
Chicago, Illinois, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
New Brunswick, New Jersey, United States
-
Study site
New York, New York, United States
-
Study site
Durham, North Carolina, United States
-
Study site
Cincinnati, Ohio, United States
-
Study site
Oklahoma City, Oklahoma, United States
-
Study site
Pittsburgh, Pennsylvania, United States
-
Study site
Charleston, South Carolina, United States
-
Study site
Memphis, Tennessee, United States
-
Study site
Houston, Texas, United States
-
Study site
Burlington, Vermont, United States
-
Study site
Colchester, Vermont, United States
-
Study site
Seattle, Washington, United States
-
Study site
Milwaukee, Wisconsin, United States
Conditions
Explore the condition pages connected to this study.